Using the NYHA Classification as Forecasting Tool for Hospital Readmission and Mortality in Heart Failure Patients with COVID-19.
COVID-19
NYHA classification
SARS-CoV-2
heart failure
mortality risk
rehospitalization
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
02 Mar 2022
02 Mar 2022
Historique:
received:
05
02
2022
revised:
21
02
2022
accepted:
01
03
2022
entrez:
10
3
2022
pubmed:
11
3
2022
medline:
11
3
2022
Statut:
epublish
Résumé
During the COVID-19 pandemic, it was observed that patients with heart disease are more likely to be hospitalized and develop severe COVID-19. Cardiac disease takes the top position among patient comorbidities, heart failure (HF) prevalence reaching almost 5% in the general population older than 35 years in Romania. This retrospective study aimed to determine the potential use of the NYHA classification for HF in hospitalized patients with COVID-19 as prognostic tool for in-hospital mortality, length of hospitalization, and probability of rehospitalization for HF decompensation. We observed that patients with advanced HF had a history of significantly more comorbid conditions that are associated with worse disease outcomes than the rest of patients classified as NYHA I and II. However, regardless of existing diseases, NYHA III, and, especially, NYHA IV, patients were at greatest risk for mortality following SARS-CoV-2 infection. They required significantly longer durations of hospitalization, ICU admission for mechanical ventilation, and developed multiple severe complications. NYHA IV patients required a median duration of 20 days of hospitalization, and their in-hospital mortality was as high as 47.8%. Cardiac biomarkers were significantly altered in patients with SARS-CoV-2 and advanced HF. Although the study sample was small, all patients with NYHA IV who recovered from COVID-19 required a rehospitalization in the following month, and 65.2% of the patients at initial presentation died during the next six months. The most significant risk factor for mortality was the development of severe in-hospital complications (OR = 4.38), while ICU admission was the strongest predictor for rehospitalization (OR = 5.19). Our result highlights that HF patients continue to be vulnerable post SARS-CoV-2 infection. Physicians and policymakers should consider this population's high likelihood of hospital readmissions when making discharge, hospital capacity planning, and post-discharge patient monitoring choices.
Identifiants
pubmed: 35268473
pii: jcm11051382
doi: 10.3390/jcm11051382
pmc: PMC8910859
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Cardiovasc Dev Dis. 2021 Jun 30;8(7):
pubmed: 34209143
Biomedicines. 2021 Aug 04;9(8):
pubmed: 34440161
ESC Heart Fail. 2021 Oct;8(5):4119-4129
pubmed: 34390216
J Clin Med. 2021 Nov 27;10(23):
pubmed: 34884277
Am J Cardiol. 2020 Apr 15;125(8):1194-1201
pubmed: 32106929
J Clin Med. 2020 Jun 22;9(6):
pubmed: 32580344
Front Immunol. 2020 Oct 22;11:570681
pubmed: 33193350
Eur Heart J Qual Care Clin Outcomes. 2018 Jan 1;4(1):51-58
pubmed: 28950356
Front Cardiovasc Med. 2021 Apr 23;8:634291
pubmed: 33969006
J Clin Med. 2022 Jan 03;11(1):
pubmed: 35011982
J Card Fail. 2020 Jun;26(6):470-475
pubmed: 32315733
Am J Emerg Med. 2021 Aug;46:204-211
pubmed: 33071085
Front Med (Lausanne). 2021 Dec 15;8:760265
pubmed: 34977066
J Clin Med. 2021 Jun 16;10(12):
pubmed: 34208640
Int J Mol Sci. 2021 May 12;22(10):
pubmed: 34066226
Chem Biol Interact. 2022 Jan 5;351:109738
pubmed: 34740598
JAMA. 2021 Jan 19;325(3):304-306
pubmed: 33315057
Eur Heart J. 2022 Mar 14;43(11):1104-1120
pubmed: 34734634
Circ Res. 2016 Apr 15;118(8):1313-26
pubmed: 27081112
Ther Adv Respir Dis. 2021 Jan-Dec;15:1753466621995050
pubmed: 33749408
Postgrad Med J. 2021 Mar;97(1145):175-179
pubmed: 32732260
South Med J. 2021 Jan;114(1):51-56
pubmed: 33398362
Eur Heart J. 2020 May 14;41(19):1807-1809
pubmed: 32383758